KP879

KP879 is an investigational, extended-duration, agonist replacement therapy being developed for the treatment of stimulant use disorder (SUD). It utilizes serdexmethylphenidate (SDX), a prodrug of d-methylphenidate (d-MPH), as its active pharmaceutical ingredient. SDX is designed to provide a delayed onset and prolonged duration of action compared to dexmethylphenidate, with the goal of reducing abuse potential and supporting sustained therapeutic effects. KP879 leverages KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug technology platform. The drug is intended to address the unmet need for FDA-approved pharmacotherapies in SUD and may represent the first such approved medication if successful[1][3][4][6].